NEW YORK, NY / ACCESSWIRE / October 5, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
LFST Shareholders Click Here: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=32425&wire=1
SFIX Shareholders Click Here: https://www.zlk.com/pslra-1/stitch-fix-class-action-loss-submission-form?prid=32425&wire=1
MDT Shareholders Click Here: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=32425&wire=1
* ADDITIONAL INFORMATION BELOW *
LifeStance Health Group, Inc. (NASDAQ:LFST)
This lawsuit is on behalf of all purchasers of LifeStance common stock pursuant and/or traceable to the documents issued in connection with LifeStance’s June 10, 2021 initial public stock offering.
Lead Plaintiff Deadline: October 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=32425&wire=1
According to the filed complaint, (i) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health’s out-patient/virtual revenue growth; (ii) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health’s operating expenses to increase substantially; (iii) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the initial public offering’s registration statement, and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health’s business metrics and financial prospects were not as strong as the initial public offering’s registration statement represented.
Stitch Fix, Inc. (NASDAQ:SFIX)
This lawsuit is on behalf of purchasers of Stitch Fix Class A common stock between December 8, 2020, and March 8, 2022, inclusive.
Lead Plaintiff Deadline: October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/stitch-fix-class-action-loss-submission-form?prid=32425&wire=1
According to the filed complaint, Stitch Fix made numerous false and misleading statements to investors concerning the synergy between the Company’s Fix and Freestyle programs, and repeatedly denied claims that the Freestyle program could cannibalize the Company’s legacy Fix business. Specifically, Stitch Fix repeatedly assured investors that the Company’s Freestyle business was “an additive experience” and “complementary” to the Fix business, that “the combination of those two things will allow us to address many more types of clients,” and that “we see solid growth in both sides of the business.” In truth, Stitch Fix concealed that these programs were not complementary or additive. Stitch Fix knew that the Freestyle program would be much preferred to the Company’s original Fix model and that the Freestyle program would inevitably cannibalize the Company’s legacy Fix business.
Medtronic plc (NYSE:MDT)
This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.
Lead Plaintiff Deadline: November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=32425&wire=1
According to the filed complaint, (1) Medtronic’s product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of the Company’s misconduct, the U.S. Food and Drug Administration would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company’s need to improve its quality control systems, would negatively affect the Company’s financial performance and cause Medtronic to fall further behind its competitors; and (6) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/719266/CLASS-ACTION-UPDATE-for-LFST-SFIX-and-MDT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
